Sajid S Qureshi1, Monica Bhagat2, Caleb Harris2, Girish Chinnaswamy3, Tushar Vora3, Seema Kembhavi4, Maya Prasad3, Mukta Ramadwar5, Omshree Shetty5, Siddharth Laskar6, Nehal Khanna6, Nayna Amin7, Sanjay Talole8. 1. Division of Pediatric Surgical Oncology, Department of Surgical Oncology, Tata Memorial Centre, Ernest Borges Road, Parel, Bombay, 400012, India. sajidshafiques@hotmail.com. 2. Division of Pediatric Surgical Oncology, Department of Surgical Oncology, Tata Memorial Centre, Ernest Borges Road, Parel, Bombay, 400012, India. 3. Division of Pediatric Oncology, Department of Medical Oncology, Tata Memorial Centre, Bombay, India. 4. Department of Radiology, Tata Memorial Centre, Bombay, India. 5. Department of Pathology and Molecular Genetics, Tata Memorial Centre, Bombay, India. 6. Department of Radiation Oncology, Tata Memorial Centre, Bombay, India. 7. Department of Anaesthesia, Tata Memorial Centre, Bombay, India. 8. Department of Biostatistics, Tata Memorial Centre, Bombay, India.
Abstract
PURPOSE: The treatment of intermediate risk (IR) neuroblastoma has evolved with the focus now on reducing the drugs, dosage, and duration of chemotherapy. The aim of this study is to present the outcomes of treatment and the complications of surgery in patients with IR neuroblastoma treated at a tertiary cancer center in India. METHODS: All eligible patients with IR neuroblastoma treated between April 2005 and August 2016 were identified. The presence and number of image-defined risk factors (IDRF) before and after neoadjuvant chemotherapy were retrospectively analyzed as were the extent of surgery, complications, and outcomes. RESULTS: Of 282 neuroblastoma patients treated during the study period, 54 had IR neuroblastoma. Complete excision was achieved in 25 patients. There were 26 surgical complications in 22 patients with a similar incidence in patients with complete (n = 13) or incomplete (n = 13) resection (p = 0.78). After a median follow-up of 47 months, the 4-year overall and event-free survival was 91.5% and 75%, respectively. There was no difference in survival between patients who underwent complete resection versus those with incomplete resection (p = 0.9). CONCLUSION: Outcomes of IR neuroblastoma are favorable. The extent of resection does not affect the survival and complications can occur even when the resection is incomplete.
PURPOSE: The treatment of intermediate risk (IR) neuroblastoma has evolved with the focus now on reducing the drugs, dosage, and duration of chemotherapy. The aim of this study is to present the outcomes of treatment and the complications of surgery in patients with IR neuroblastoma treated at a tertiary cancer center in India. METHODS: All eligible patients with IR neuroblastoma treated between April 2005 and August 2016 were identified. The presence and number of image-defined risk factors (IDRF) before and after neoadjuvant chemotherapy were retrospectively analyzed as were the extent of surgery, complications, and outcomes. RESULTS: Of 282 neuroblastomapatients treated during the study period, 54 had IR neuroblastoma. Complete excision was achieved in 25 patients. There were 26 surgical complications in 22 patients with a similar incidence in patients with complete (n = 13) or incomplete (n = 13) resection (p = 0.78). After a median follow-up of 47 months, the 4-year overall and event-free survival was 91.5% and 75%, respectively. There was no difference in survival between patients who underwent complete resection versus those with incomplete resection (p = 0.9). CONCLUSION: Outcomes of IR neuroblastoma are favorable. The extent of resection does not affect the survival and complications can occur even when the resection is incomplete.
Authors: H J Nickerson; K K Matthay; R C Seeger; G M Brodeur; H Shimada; C Perez; J B Atkinson; M Selch; R B Gerbing; D O Stram; J Lukens Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: Giovanni Cecchetto; Veronique Mosseri; Bruno De Bernardi; Pierre Helardot; Tom Monclair; Elisa Costa; Ernst Horcher; Sylvia Neuenschwander; Paolo Tomà; Antonino Rizzo; Jean Michon; Keith Holmes Journal: J Clin Oncol Date: 2005-11-20 Impact factor: 44.544
Authors: K K Matthay; C Perez; R C Seeger; G M Brodeur; H Shimada; J B Atkinson; C T Black; R Gerbing; G M Haase; D O Stram; P Swift; J N Lukens Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Ian Magrath; Eva Steliarova-Foucher; Sidnei Epelman; Raul C Ribeiro; Mhamed Harif; Chi-Kong Li; Rejin Kebudi; Scott D Macfarlane; Scott C Howard Journal: Lancet Oncol Date: 2013-02-20 Impact factor: 41.316
Authors: J A Kohler; H Rubie; V Castel; K Beiske; K Holmes; C Gambini; F Casale; C Munzer; G Erminio; S Parodi; S Navarro; C Marquez; M Peuchmaur; C Cullinane; P Brock; D Valteau-Couanet; A Garaventa; R Haupt Journal: Eur J Cancer Date: 2013-07-29 Impact factor: 9.162
Authors: Shakeel Modak; Brian H Kushner; Michael P LaQuaglia; Kim Kramer; Nai-Kong V Cheung Journal: Eur J Cancer Date: 2008-11-06 Impact factor: 9.162
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544